<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03738670</url>
  </required_header>
  <id_info>
    <org_study_id>7010</org_study_id>
    <nct_id>NCT03738670</nct_id>
  </id_info>
  <brief_title>Bipolar RFA of Painful Extra-spinal Bone Metastases</brief_title>
  <acronym>PERFACOOL</acronym>
  <official_title>Pain Evaluation After Treatment of Extra-spinal Bone Metastases With OsteoCOOL Radiofrequency (RF) Ablation System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the worst pain of cancer patients with painful extra-spinal bone metastases 1
      month after bipolar radiofrequency ablation (RFA) performed with the Osteocool system.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2019</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of responding patients reporting an improvement of at least 3 points on item 3 &quot;the worst pain in the last 24 hours&quot; of Brief Pain Inventory (BPI) questionnaire</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the mean scores of the items 3, 5, 9B and 8 of the BPI questionnaire between the baseline and 6-month follow-up</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be assessed according to SIR(11) / CTCAE classification</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean scores variation of the morphine milligram equivalents (MME) (based on patient consumption diary) between the baseline and 6-month follow-up.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responding patients defined by an improvement of at least 3 points on item 3 &quot;the worst pain in the last 24 hours&quot; of Brief Pain Inventory (BPI) questionnaire at 3 and 6 month follow-up.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Multi-metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>RFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-arm prospective observational study</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous RFA</intervention_name>
    <description>Single session percutaneous extra-spinal bone metastasis destruction to achieve pain relief</description>
    <arm_group_label>RFA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) Multi-metastatic cancer patients with at least one painful lytic bone metastasis

          -  2) Target lesion should correspond to a specific radiologic finding

          -  3) At least a moderate pain produce by target lesion (4 on a scale of 0 to 10 over the
             prior 24 hours with or without pain killers intake) assessed during selection
             evaluation

          -  4) Patients 18 years old

          -  5) Able to give written consent

          -  6) Life expectancy 1 months

          -  7) Patient affiliated to the National Health Insurance system

        Exclusion Criteria:

          1. Radiation therapy on the target tumor terminated &lt; 3 weeks before treatment

          2. Any contra-indication for the procedure as stated by the radiologist in terms of tumor
             size, proximity to neural/vascular structures making the procedure at unacceptable
             risk

          3. Any contra-indication for the procedure as stated by the radiologist related to
             patient's condition (e.g. cardiac pacemakers) making the procedure at unacceptable
             risk

          4. Impaired haemostasis

          5. Concurrent participation in other experimental studies that could affect endpoints of
             this study

          6. Contraindication to any form of sedation/anaesthesia

          7. Signs of local/systemic infection identified before procedure, in accordance with
             standard care

          8. Sclerotic metastases

          9. Adults under guardianship

         10. Patients under judicial protection

         11. Pregnant or breastfeeding woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luigi Roberto CAZZATO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Strasbourg, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luigi Roberto CAZZATO, MD</last_name>
    <phone>3 69 55 16 35</phone>
    <phone_ext>0033</phone_ext>
    <email>robertoluigi.cazzato@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital, Strasbourg, france</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Roberto CAZZATO, MD</last_name>
      <phone>3 69 55 16 35</phone>
      <phone_ext>0033</phone_ext>
      <email>robertoluigi.cazzato@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 5, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Extra-spinal</keyword>
  <keyword>RFA</keyword>
  <keyword>Radiofrequency ablation</keyword>
  <keyword>Bone metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

